[DRNA] Dicerna Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 65.71 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.2 Change: 0.15 (4.92%)
Ext. hours: Change: 0 (0%)

chart DRNA

Refresh chart

Strongest Trends Summary For DRNA

DRNA is in the long-term up 289% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company?s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including hemophilia, porphyria, hypercholesterolemia, hemoglobinopathies, alpha-1-antitrypsin deficiency hepatocyte, inclusions, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated, as well as a product candidate targeting the oncogene KRAS; and a second product candidate targeting an oncogene. The company has a research collaboration and license agreement with Kyowa Hakko Ki

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding20.73 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV0.76 Price/Cash Per Share0.75
Price/Free Cash Flow-1.79 ROA-55.23% ROE-59.06% ROI
Current Ratio14.81 Quick Ratio Long Term Debt/Equity Debt Ratio0.07
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities150 K Cash From Investing Activities7.07 M Cash From Operating Activities-10.65 M Gross Profit
Net Profit-14.08 M Operating Profit-14.14 M Total Assets92.75 M Total Current Assets89.09 M
Total Current Liabilities6.02 M Total Debt Total Liabilities6.02 M Total Revenue
Technical Data
High 52 week17.69 Low 52 week9.67 Last close12.1 Last change3.07%
RSI39.62 Average true range0.75 Beta1.55 Volume169.43 K
Simple moving average 20 days-3.86% Simple moving average 50 days-8.83% Simple moving average 200 days-8.01%
Performance Data
Performance Week6.23% Performance Month-12% Performance Quart5.77% Performance Half-11.74%
Performance Year-12.1% Performance Year-to-date13.19% Volatility daily3.16% Volatility weekly7.08%
Volatility monthly14.5% Volatility yearly50.23% Relative Volume366.28% Average Volume536.93 K
New High New Low

News

2019-06-21 07:30:00 | Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 PH1 and Type 2 PH2

2019-06-20 07:30:00 | Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria

2019-06-18 11:45:21 | Did The Underlying Business Drive Dicerna Pharmaceuticals's NASDAQ:DRNA Lovely 393% Share Price Gain?

2019-06-13 07:30:00 | Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy

2019-06-12 16:04:01 | Bain's second life sciences fund comes in over $1 billion

2019-06-11 18:57:08 | Here’s What Hedge Funds Think About Dicerna Pharmaceuticals Inc DRNA

2019-06-04 07:30:00 | Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer

2019-06-03 16:30:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-05-28 16:05:00 | Dicerna™ to Present at the Jefferies 2019 Healthcare Conference

2019-05-16 07:30:00 | Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus

2019-05-10 18:09:38 | Edited Transcript of DRNA earnings conference call or presentation 9-May-19 8:30pm GMT

2019-05-09 21:24:08 | Dicerna Pharmaceuticals Inc DRNA Q1 2019 Earnings Call Transcript

2019-05-09 19:15:11 | Dicerna Pharmaceuticals DRNA Reports Q1 Loss, Lags Revenue Estimates

2019-05-09 18:07:21 | Dicerna Pharmaceuticals: 1Q Earnings Snapshot

2019-05-09 16:05:00 | Dicerna™ Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update

2019-05-07 11:47:24 | Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc DRNA

2019-05-03 16:05:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-05-02 16:05:00 | Dicerna™ to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019

2019-05-02 07:30:00 | Dicerna™ Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria PH for the PHYOX™2 Pivotal Trial

2019-04-16 14:39:01 | Bain Capital raising another life sciences fund after $720M debut

2019-04-11 09:27:01 | 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

2019-04-01 16:30:00 | Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-04-01 16:05:00 | Dicerna™ to Present at the H.C. Wainwright Global Life Sciences Conference

2019-03-29 06:30:00 | Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 PH1 and Type 2 PH2

2019-03-12 01:34:48 | Edited Transcript of DRNA earnings conference call or presentation 11-Mar-19 8:30pm GMT

2019-03-11 21:28:07 | Dicerna Pharmaceuticals Inc DRNA Q4 2018 Earnings Conference Call Transcript

2019-03-11 17:35:09 | Dicerna Pharmaceuticals DRNA Reports Q4 Loss, Lags Revenue Estimates

2019-03-11 16:42:22 | Dicerna Pharmaceuticals: 4Q Earnings Snapshot

2019-03-11 16:05:00 | Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update

2019-03-11 14:30:00 | Dicerna Pharmaceuticals, Inc. to Host Earnings Call

2019-03-06 08:30:00 | New Research: Key Drivers of Growth for Energy Transfer LP, Domo, Accenture, Chevron, Cincinnati Financial, and Dicerna Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

2019-03-04 16:05:00 | Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019

2019-03-01 16:30:00 | Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-02-22 16:49:00 | Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

2019-02-21 09:10:00 | ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth

2019-02-12 13:17:00 | Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer

2019-02-05 07:35:00 | Recent Analysis Shows DICK'S Sporting Goods, Zix, Q2, InfraREIT, The Boston Beer, and Dicerna Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-01 16:30:00 | Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-01-28 07:30:00 | Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus

2019-01-24 07:30:00 | Dicerna Evolves Its Board of Directors to Support Continued Growth

2019-01-08 16:05:00 | Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635c4

2019-01-04 07:00:00 | Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna

2018-12-20 07:30:00 | Dicerna to Join NASDAQ Biotechnology Index

2018-12-19 07:30:00 | Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company

2018-12-15 23:06:44 | Here is What Hedge Funds Think About Dicerna Pharmaceuticals Inc DRNA

2018-11-30 07:45:00 | Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-29 07:30:00 | Dicerna to Participate in Citi’s 2018 Global Healthcare Conference

2018-11-28 13:05:22 | Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

2018-11-26 11:33:36 | Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date

2018-11-09 08:00:00 | Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018